Galderma R&D
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Galderma R&D sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).
Galderma R&D: 158 sponsored US clinical trials, 7 recruiting.
Galderma R&D sponsors 158 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 142 completed. 90 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 7 trials.
Top-decile sponsor footprint
Galderma R&D ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 146 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
158 total, page 3 of 4
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
NCT01426269
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355458
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355471
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
NCT01308619
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
NCT01320033
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01318733
Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
NCT01213199
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
NCT01209949
Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds
NCT01205061
Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds
NCT01205048
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01174030
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
NCT01139047
Epiduo Pediatric Acne Study
NCT01138735
Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin
NCT01139008
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne
NCT01106807
Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
NCT01046565
Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
NCT01046396
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
NCT00988637
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
NCT00989014
Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis
NCT00941317
Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
NCT00907101
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
NCT00919763
ORCA - Oracea® for Rosacea: A Community-based Assessment
NCT00892281
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
NCT00881868
Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance
NCT00687908
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
NCT00763503
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
NCT00763555
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
NCT00688064
Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections
NCT00716443
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
NCT00660985
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
NCT00697541
Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage
NCT00647556
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
NCT01892657
Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
NCT00658788
An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%
NCT00668655
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
NCT00669071
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
NCT00671749
Treatment of Patients With Blepharitis and Facial Rosacea
NCT00560703
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
NCT00599521
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
NCT00598832
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
NCT00306800
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
NCT00733954
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
NCT00441415
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
NCT00472966
A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
NCT00421993
A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
NCT00419666
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
NCT01892423
Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application
NCT00436527
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
NCT00437255
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
NCT00422240
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 24 |
| Phase 3 | 41 |
| Phase 4 | 49 |
Therapeutic Areas
Where Galderma R&D enrollment is open (later-stage tilt)
7 recruiting of 158 indexed (4% open); 142 completed (90%).
Phase mix: 90 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Acne Vulgaris (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Galderma R&D: open-pipeline peers nationwide
Peers matched on 158 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Galderma R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 158 trials (± recruiting share)
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
- Ann & Robert H Lurie Children's Hospital of Chicago · 159 trials · 19% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
Related
What to do with this Galderma R&D page
158 registered trials is a research-attention snapshot, not an endorsement of Galderma R&D or any single study.
- 7 of Galderma R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Galderma R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Galderma R&D pipeline card: 158 registered trials from official public datasets.Report a data error.